BACH1 and HIF1 alpha predict response to neoadjuvant nab-paclitaxel (nP) treatment in early breast cancer (BC) (2021) Vladimirova V, Schneeweiss A, Jackisch C, Weber KE, Denkert C, Schmatloch S, Karn T, et al. Conference contribution Baseline menopausal status, Ki-67 and stromal tumour-infiltrating lymphocytes (TILs) and association with outcome in triple-negative breast cancer (TNBC): Exploratory analysis in GeparSixto (2021) Labidi-Galy SI, Schneeweiss A, Sinn HP, Blohmer JU, Romanens L, Zahm DM, Huober J, et al. Conference contribution Impact of body mass index (BMI) on prognostic and predictive value of stromal tumour-infiltrating lymphocytes (sTILs) in triple-negative breast cancer (TNBC): A pooled analysis of six neoadjuvant trials (2021) Furlanetto J, Denkert C, Untch M, Sinn B, Lederer B, Schneeweiss A, Mueller V, et al. Conference contribution Association of RAD51 with homologous recombination deficiency (HRD) and clinical outcomes in untreated triple-negative breast cancer (TNBC): Analysis of the GeparSixto randomized clinical trial (2021) Llop-Guevara A, Vladimirova V, Schneeweiss A, Villacampa G, Karn T, Zahm DM, Herencia-Ropero A, et al. Journal article, Original article Pooled analysis of patient (pt)-reported outcomes (PROs) in the MONALEESA (ML)-2,-3, and-7 trials: Additional results and key subgroup findings (2021) Fasching P, Bardia A, Nusch A, Jerusalem G, Chan A, El Saghir NS, Conejo EA, et al. Conference contribution Epigenetic regulation of the putative breast cancer metastasis suppressor gene SCN4B (2021) Hilgers L, Hartmann A, Fasching P, Villwock S, Moll L, Roger S, Knuechel-Clarke R, et al. Conference contribution Association of RAD51 with homologous recombination deficiency (HRD) and clinical outcomes in untreated triple-negative breast cancer (TNBC): analysis of the GeparSixto randomized clinical trial (2021) Llop-Guevara A, Loibl S, Villacampa G, Vladimirova V, Schneeweiss A, Karn T, Zahm DM, et al. Journal article Association of quality of life (QOL) with overall survival (OS) in patients (pts) with HR+/HER2-advanced breast cancer (ABC) treated with ribociclib (RIB) plus endocrine therapy (ET) in the MONALEESA-3 (ML-3) and ML-7 trials (2021) Fasching P, Harbeck N, Jerusalem G, Colleoni MA, Neven P, Franke F, De Laurentiis M, et al. Conference contribution The phase III NETTER-1 study of 177Lu-DOTATATE in patients with midgut neuroendocrine tumours: Further survival analyses (2021) Ruszniewski PB, Caplin ME, Kunz PL, Bodei L, Hendifar AE, Mittra E, Wolin EM, et al. Conference contribution PACIFIC-R real-world study: Treatment duration and interim analysis of progression-free survival in unresectable stage III NSCLC patients treated with durvalumab after chemoradiotherapy (2021) Girard N, Smit HJM, Sibille A, Mcdonald F, Mornex F, Garassino MCC, Filippi AR, et al. Conference contribution